The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Identifying and blocking chemokine inflammatory mediators in pediatric opsoclonus–myoclonus syndrome (OMS) is critical to the treatment of this autoimmune, paraneoplastic, neurological disorder. In a prospective, case-control, clinico-scientific study of children with OMS compared to non-inflammatory neurological controls and other inflammatory neurological disorders, CCL19 (n=369) and CCL21 (n=312)...
Pediatric opsoclonus–myoclonus syndrome (OMS) is a neuroblastoma-associated neuroinflammatory disorder. The purpose of this study was to evaluate the capacity of immunotherapies used in treating OMS to normalize several putative biomarkers of disease activity. Soluble BAFF and APRIL and a variety of chemokine ligands for CXCR3, CXCR5, CCR4, CCR7 were measured in cerebrospinal fluid (CSF) and serum...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.